Entrepreneurship Bootcamp Session 2 - Project, Product or Company - PowerPoint PPT Presentation

1 1 Entrepreneurship Bootcamp Session 2 - Project, Product or Company Mark A. Tepper, Ph.D. President & CSO Corbus Pharmaceuticals Inc. June 3, 2018

Developing Medicines which modulate the endocannabinoid system

JB Therapeutics: Highlights Targeted Cannabinoid Agonists and Antagonists for the treatment of: Market •Pain: ~$30 Billion Rx market Focus •Obesity: ~$15 Billion Rx market •CNS disorders: ~$20 Billion market (PTSD, Anxiety, neurodegenerative diseases) • Orally active non-psychotropic CB1/2 agonist for chronic pain Technology • Peripheral CB1 Antagonist for Obesity • CB2 Agonist for Inflammatory Pain • FAAH inhibitor for Neurodegenerative disease • Oral Endocannabinoid mimetics • Advance programs to Phase II POC Development • Partner out select programs Strategy • Bring internal neurodegenerative disease programs to market. • Seek funding of $5M to complete POC clinical studies with lead Financing CB1/CB2 agonist for pain Plan • Management team experienced in building biotech companies Leadership • 60+ yrs operating experience in drug discovery and development

Mark Tepper, PhD – CEO Paul Goldenheim, MD -Former CMO, Purdue Pharm -BMS, Serono -Analgesic Research -Former CEO - NKT Therapeutics, RXi Pharmaceuticals, Arradial Nathan Katz, MD Kollol Pal, PhD – SVP R&D -CEO Analgesic Research -Advisor to FDA on analgesia -BIPI, Mitotix, Neogenesis, Satori -Former CEO, Rishi Pharma George Kunos, MD, PhD Terry Plasse, MD – Clinical -NIH Section Head, Pain & Analgesia Lynn Van Campen, PhD Consultant -Former Clinical developer of Marinol -Former VP, Inhale Therapeutics, BIPI -University of Wisconsin Sumner Burstein, PhD -Prof. Emeritus, Biochemistry Umass Medical School -Inventor of JBT-101 Robert Zurier, MD -Prof. of Medicine, Rheumatology UMass Medical School

CB1 & CB2 Signaling Pathway PNS EC EC CB2 CB2 NRDD, 2008

Cannabinoids in Medicine Therapeutic Cannabinoids have long history of 1981 Validation human efficacy and safety in analgesia, emesis, MS spasticity, and neuropathic pain High JBT-101 has > potency to natural and Potency synthetic cannabinoid drugs on the 1985 market No Adverse JBT-101 has reduced penetration of BBB and therefore does not induce Side- psychotropic side effects like Marinol, Effects Nabilone or Sativex Potential Chronic Pain, Chronic inflammatory 2005 diseases, GI disorders, angiogenesis, Indications multiple sclerosis spasticity Ki (nM) huCB1 huCB2 THC (Marinol)* 80.5nM 31.9nM DMH-THC* 0.27nM 0.20nM Nabilone (Cesamet)* 2.2nM 1.8nM 5.7nM 56nM JBT-101 *psychotropic

JBT-101 (Ajulemic Acid) • Orally Active Non-psychotropic CB1/2 agonist 11 COOH 9 • Effective in 15 animal models of Pain & 8 OH Inflammation R 1 - Analgesic effects: 1–10 mg/kg R - Anti-inflammatory effects: 0.1-1 mg/kg 1' -Modulate inflammatory mediators: PGJ, LXA4 O - Prevents inflammatory destruction 3 -Suppress IL1 β , IL6, IL8 -Suppress MMP1, MMP3, MMP9 JBT-101 • Clinical Studies - 150 patients/volunteers safely treated MW = 400.55 - Completed Phase I (US, Eu) T 1/2 = ~4 Hr - Completed Phase IIa in Neuropathic Pain Ki (CB1/2) = 5.7 nM/56 nM EC50 (CB1/2) = 11.6 nM/13.4 nM MTD > 100mg/kg ED 50 = 0.5 - 5mg/kg Dual Analgesic & Anti-inflammatory Drug

Unique Product Profile to Treat OA and Pain Anti- No Side Effects No Abuse Inflam Potential Drug Analgesic CNS CV Resp GI        JBT-101 Opiates  X  X X X X NSAIDs       X Antidepressants   X X X X X Anticonvulsants COX-2 Inhibitors    X    JBT-101 safer than opiates, NSAIDs and Cox-2 Inh with potential to treat inflammation and pain

JBT-101 Clinical Trials Summary Phase I II Re Refra ract ctory Ch Chro ronic N c NP Phase I e I SAD D - 21 p 21 pat atie ients w wit ith > > 6 6 months - 32 healthy vo y volunteer eers continuo nuous us N NP p pain - Single a asc scending d dose ose desi esign-10m 10mg - 20 20 mg => 40 m 40 mg, p , po, bid , bid, , x7 d 7 day ays - Endpoin ints: P PK, Safety, Tole lerabili ility - Endpoints: E : Effic icac acy, S , Saf afety, T , Tolerability Phase I e I SAD/ D/MAD - 104 h 104 heal althy v volu lunteers - Sin ingle d dose: 10, 20, 40, 10, 20, 40, 80, 120, 80, 120, 150, 150, 180, 180, o or 280 280mg - Mult ltiple d doses : : 20, 20, 40 40 & 80m 80mg, , tid id - Endpoints: : PK, , AEs, S , Saf afety, M MTD JBT-101 dosed orally in 150 patients/volunteers

Cohort 1 Cohort 2 Active vs Placebo Active vs Placebo Primary Endpoint: VAS Reduction 31% vs 2%* 18% vs 5%* Secondary Endpoint: Responders ( >30% pain reduction) 67% vs 10% 20% vs 10% VRS Reduction 20% vs 4%** 16% vs 1%** Allodynia Pressure Test Variable Variable Global Impression Score (CGI) Cohort 1 & 2 combined Clear improvement 11 patients No ∆ between active and placebo groups NIDA Addiction Research Center Inventory- Marijuana (ARCI-M) Safety & Adverse Events No safety issues No ∆ in AEs between active, placebo and baseline • p< 0.032; **p< 0.052 • N=21 patients

Timeline 2H09 1Q10 2Q10 3Q10 4Q10 1Q11 2Q11 3Q11 4Q11 1Q12 2Q12 Pre- File IND JBT Mtg IND FDA required Non-Clinical Studies (if necessary) 200gm API Clinical API (JBT) Campaign Phase Ib Lupus Study CRO#2 (Feinstein-JBT SBIR Grant) 0.4Kg 5Kg Generate Bridge Develop SR Phase 2a JBT-101SR Clinical Drug PK formulation in NP Product w/ SR CRO#1 CRO#1 (JBT) Milestones: 2 Clinical trails + SR formulation

JBT-101 Patent Estate 200 2008 200 2009 2010 201 2015 201 202 2020 203 2030 203 2031 199 1992 US 5, 5,338 338,753 53 – JB JBT10 101 C Comp mp o of matte matter - NCE data exc xclu lusivi vity y & O Orphan D Drug g 2010 2010– Comp mposi sition, Dose se & Sustai stained-rel elea ease 201 2011– Met ethod of of Use e – JB JBT10 101 1 Fibr brotic Dise sease se IP Couns unsel Landro ro & Anast stasi si 201 2011– Improved Pharma maceutic tical l Compositio ition Clark & Elbin Cla ing & Meth thod of Synth thesis is JBT-101 F JB Franch chise C Cove vere red Through ~ ~ 2031

13 Market Opportunity- Franchise in a product

• First non-psychotropic CB1/CB2 Agonist for treating pain and Product inflammation • POC established in refractory neuropathic pain patients • 1 Phase 2, 1 Preclinical and 2 lead optimization programs Pipeline targeting endocannabinoid system • Multiple formats – sustained release, topical, patch • Multiple indications & combinations with NSAIDs, opioids • Large unmet medical need- Market • Pain, Obesity, Neurodegenerative Disease- All $ billion markets • Seeking Funding of $5 Million to complete Phase 2 POC studies Investor with SR formulation Opportunity • Advance preclinical pipeline

15 Corbus Pivots Risks Original Current Product Single Asset, 1 large Single asset multiple indication indications IP Limited IP life with 5 Issued IP to 2033 + ODD yr NCE protection Team 2FTEs Mgmt + 4 FTEs Mgmt w 120 yr consultants experience -62 total FTEs Regulatory Repeat Tox study Phase 3 with multiple File new IND FDA/EMA mtgs with agreement on endpoints Market Large Market Niche/Orphan Financial Private/Angels Public- 45% institutions Competition Opiates, NSAIDs SSc, CF, DM, SLE (novel MOA)

16 Corbus Funding History 2009 2010 2011 2012 2013 2014 2015 Company Founding Hire CEO & CFO Series A Round- $2M SSc Animal POC Seed Round File S-1 5/15 Mtf with BfArM $11M Private Placement- 6/14 Vendor Financing-API Repeat Tox Study List on NASDAQ-5/15 FDA Pre-IND Mtg- SSc Mfg DS & DP Hire CMO FDA pre-IND Mtg-NP Convertible Note SSc &DM P2 Trails $25M CFF Completed $27M $37M Award $5M CFF Award CF P2b Trial Financing Financing S-3 NASDAQ Listing Initiated $100M $11M Warrant Call SSc &DM $11M Private P2 Trails CF CF Placement- 6/14 SSc P3 Initiated P2 Trail P2 Trail Trail Initiated Completed Initiated S-3 File IND $200M S-1 Filing CF SSc ODD ODD

Thank You! 17

18 Back Up Slides

JBT-101: Analgesic Activity Writhing Model Analgesia Model Formalin Test 11 9 RESPONSE [writhings] 7 5 3 1 -1 .1 1 10 100 DOSE of CT3 [mg/kg i.v.] 4.6 mg/kg JBT-101 5% formalin sc in hindpaw JBT-101 iv in 10% Cremophor Early phase: 0-15 min 0.02% phenylquinone Late phase: 15-30 min JBT-101 reversed PAF induced Allodynia, improved analgesia Life Sci, 1998 Neurosci, 2000 Reduces Pain in Animal Models

JBT-101: Anti-inflammatory Activity 100 CONTROL CT3 TREATED % JOINTS SHOWING ANKYLOSIS 80 60 40 20 0 1 Reduces Inflammation & Joint Damage in Arthritis Model